Chinese Journal of Tissue Engineering Research ›› 2025, Vol. 29 ›› Issue (23): 5041-5050.doi: 10.12307/2025.065

Previous Articles     Next Articles

Molecular mechanism of adipose tissue-derived mesenchymal stem cells in treatment of acute liver injury

Yang Na, Liu Yang, Hao Huiqin   

  1. Basic Laboratory of Integrative Medicine, Shanxi University of Traditional Chinese Medicine, Jinzhong 030619, Shanxi Province, China
  • Received:2024-01-15 Accepted:2024-04-30 Online:2025-08-18 Published:2024-09-30
  • Contact: Hao Huiqin, MD, Chief physician, Professor, Doctoral supervisor, Basic Laboratory of Integrative Medicine, Shanxi University of Traditional Chinese Medicine, Jinzhong 030619, Shanxi Province, China; Co-corresponding author: Liu Yang, MD, Professor, Master’s supervisor, Basic Laboratory of Integrative Medicine, Shanxi University of Traditional Chinese Medicine, Jinzhong 030619, Shanxi Province, China
  • About author:Yang Na, MD, Lecturer, Basic Laboratory of Integrative Medicine, Shanxi University of Traditional Chinese Medicine, Jinzhong 030619, Shanxi Province, China
  • Supported by:
    Natural Science Foundation of Shanxi Province, No. 202203021222272 (to YN); Key Scientific Research Innovation Team Project of Shanxi Province, No. 202204051002033 (to HHQ); Doctoral Scientific Research Foundation of Shanxi University of Chinese Medicine, No. 2023BK32 (to YN); Scientific Research Innovation Team Project of Shanxi University of Chinese Medicine, No. 2022TD2003; Basic Research of Integrated Traditional Chinese and Western Medicine in Rheumatic immune Diseases of Shanxi University of Chinese Medicine, No. 2023XKJS-03 (to HHQ)

Abstract: BACKGROUND: Acute liver injury can result from a variety of causes, and if not treated in time, it will develop into acute liver failure and seriously affect the life safety of patients. As the liver is the largest immune organ and metabolic organ, there is no optimal treatment for acute liver injury. The adipose tissue-derived mesenchymal stem cell has multi-differentiation potential and immunomodulatory activity, so it has been gradually becoming an effective tool for the treatment of acute liver injury.
OBJECTIVE: To review the progress and molecular mechanism of adipose tissue-derived mesenchymal stem cell and its modification in different ways in the treatment of acute liver injury.
METHODS: Relevant articles published from 2000 to 2023 were retrieved from PubMed, Web of Science, and CNKI databases. English search terms were “acute liver injury, liver injury, adipose tissue-derived mesenchymal stem cell, liver injury repair, stem cell transplantation, stem cell repair, cell surface engineering, stem cell modification.” Chinese search terms were “acute liver injury, liver injury, adipose tissue-derived mesenchymal stem cell, liver injury repair, stem cell transplantation, stem cell repair, stem cell modification.” Totally 62 articles of the latest research progress in this field were summarized and analyzed.
RESULTS AND CONCLUSION: (1) Adipose tissue-derived mesenchymal stem cell as a potential stem cell with multi-directional differentiation has biological advantages in the treatment of acute liver injury. Compared with the other two major types of mesenchymal stem cell that is bone marrow mesenchymal stem cell and umbilical cord mesenchymal stem cell, they are more widely sourced, easily accessible and have fewer ethical issues, and more self-renewal than bone marrow mesenchymal stem cell. (2) Adipose tissue-derived mesenchymal stem cell may play a therapeutic role in acute liver injury by regulating immune responses, differentiating into hepatocytes, and secreting growth factors and exosomes. It can reduce the expression of inflammatory factors in serum and the infiltration of inflammatory cells in liver tissue, also can inhibit the pyroptosis and autophagy levels to promote regeneration of sinusoidal endothelial cells and hepatocyte, and ultimately improve liver damage. At present, no studies have shown which mechanism is the best mechanism for adipose tissue-derived mesenchymal stem cells to treat acute liver injury, and most opinions believe that these molecular mechanisms interact with each other to play a synergistic role in treatment. (3) Biomaterials modification and drug pretreatment can improve the efficacy of adipose tissue-derived mesenchymal stem cell in the treatment of acute liver injury. On the one hand, biomaterials and drug modifications can enhance the functions of adipose tissue-derived mesenchymal stem cell, such as enhancing the ability of proliferation and migration, increasing the level of growth factors secreted, and enhancing the anti-inflammatory ability and promoting the survival of adipose mesenchymal stem cells at the injury site. On the other hand, biomaterials and drug modifications can inhibit the activation of inflammatory cells at the injured site and promote the growth of blood to improve the success rate of transplantation. (4) In summary, adipose tissue-derived mesenchymal stem cell plays an important role in the treatment of acute liver injury by secreting growth factors and exosomes, regulating the immune response, and promoting liver regeneration. With the development of science and technology, biomaterials and drug modification can enhance the self-renewal ability of adipose tissue-derived mesenchymal stem cell and improve the local microenvironment of acute liver injury. It provides a new way to promote the clinical application of adipose tissue-derived mesenchymal stem cell in the treatment of acute liver injury.

Key words: acute liver injury, adipose tissue-derived mesenchymal stem cell, liver, adipose tissue, cell transplantation, cell modification, cell engineering, injury repair

CLC Number: